Accidental as well as surgical trauma has been reported to cause reduced endotoxin responsiveness of blood in terms of cytokine production. In this study, the effect of interferon-γ (IFN-γ) on tumour necrosis factor-α (TNF-α)-producing capacity of whole blood after severe trauma and cardiac surgery was investigated. Blood samples of severely injured patients were collected at the first day after trauma and of cardiac surgery patients before, 4 h and 2 days after cardiopulmonary bypass (CPB). The blood samples were incubated with INF-γ (0—100 U/ml) for 20 h and subsequently lipopolysaccharide (LPS)-induced TNF-α production was determined. Compared to healthy donors, LPS-induced TNF-α production was significantly reduced in blood cultures of trauma patients on day 1 after trauma and 4 h after CPB. Pre-incubation with IFN-γ in vitro increased endotoxin-induced TNF-α production in volunteers' and all patients' blood specimens in a dose-dependent manner. IFN-γ prompted an elevation of cytokine synthesis in CPB patients' blood which equalled that of volunteers, whereas it caused a lower rise in TNF-α production in blood of multiply injured patients, reaching levels of untreated donors only after incubation with 100 U/ml IFN-γ. These experiments show that hyporesponsiveness of whole blood induced by trauma or cardiac surgery with CPB is not irreversible, but can be counteracted by the immunostimulant IFN-γ. IFN-γ, therefore, could be applied clinically in trauma patients or after cardiac surgery to prevent or to resolve infection complications.
References
1.
Bone RCToward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Crit Care Med1996; 24: 163—172.
2.
Hack CE, Aarden LA, Thijs LGRole of cytokines in sepsis. Adv Immunol1997 ; 66: 101—195.
3.
Abraham E., Wunderink R., Silverman H.et al.Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA1995; 273: 934—941.
4.
Fischer CJ, Agosti JM, Opal SM et al. Treatment of septic shock with the tumor necrosis factor/Fc fusion protein. N Engl J Med1996; 334: 1697—1702.
5.
Pfeffer K., Matsuyama T., Kundig TM et al. Mice deficient for the 55 kDa tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection . Cell1993; 73: 457—467.
6.
Flynn JL, Goldstein MM, Chan J. et al. Tumor necrosis factor-α is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity1995; 2: 561—572.
7.
D'Andrea A., Ma X., Aste Amezaga M., Paganin C., Trinchieri G.Stimulatory and inhibitory effects of interleukin (IL)-4 and IL-13 on the production of cytokines by human peripheral blood mononuclear cells: priming for IL-12 and tumor necrosis factor α production. J Exp Med1995; 181: 537—546.
8.
Taffet SM, Eurell TE, Russel SWRegulation of macrophage-mediated tumor cell killing by prostaglandins: comparison of the effects of PGE2 and PGI2. Prostaglandins1982; 24: 763—774.
9.
Fiorentino DF , Zlotnik A., Mosman TR, Howard M., O'Garra A.IL-10 inhibits cytokine production by activated macrophages. J Immunol1991; 147: 3815-3822.
10.
Seghaye M., Duchateau J., Bruniaux J. et al. Interleukin-10 release related to cardiopulmonary bypass in infants undergoing cardiac operations. J Thorac Cardiovasc Surg1996; 111: 545—553.
11.
Sablotzki A., Welters I., Lehmann N. et al. Plasma levels of immunoinhibitory cytokines interleukin-10 and transforming growth factor-beta in patients undergoing coronary artery bypass grafting. Eur J Cardiothorac Surg1997; 11: 763—768.
12.
Sherry RM, Cue JI, Goddard JK, Parramore JB, DiPiro JTInterleukin-10 is associated with the development of sepsis in trauma patients . J Trauma1996; 40: 613—616.
13.
Stefano GB, Rodriguez M., Glass R., Cesares F., Hughes TK, Bilfinger TVHyperstimulation of leukocytes by plasma from cardiopulmonary bypass patients is diminished by morphine and IL-10 pretreatment. J Cardiovasc Surg Torino1995; 36: 25—30.
14.
Lyons A., Kelly JL, Rodrick ML, Mannick JA, Lederer JAMajor injury induces increased production of interleukin-10 by cells of the immune system with a negative impact on resistance to infection. Ann Surg1997; 226: 450—458.
15.
Marchant A., Alegre ML, Hakim A. et al. Clinical and biological significance of interleukin-10 plasma levels in patients with septic shock. J Clin Immunol1995; 15: 266—273.
16.
Livingston DH, Appel SH, Wellhausen SR, Sonnenfeld G., Polk HCDepressed interferon gamma production and monocyte HLA-DR expression after severe injury. Arch Surg1988; 123: 1309—1312.
17.
Misoph M., Babin-Ebell J., Schwender S., Grossmann R., Keller F., Elert O.Response of the cellular immune system to cardiopulmonary bypass in vivo. Thorac Cardiovasc Surg1997; 45: 217—223.
18.
Keel M., Schregenberger N., Steckholzer U. et al. Endotoxin tolerance after severe injury and its regulatory mechanisms . J Trauma1996; 41: 430—437.
19.
Majetschak M., Flach R., Heukamp T. et al. Regulation of whole blood tumor necrosis factor production upon endotoxin stimulation after severe blunt trauma. J Trauma1997; 43: 1—8.
20.
Hensler T., Hecker H., Heeg K. et al. Distinct mechanisms of immunosuppression as a consequence of major surgery. Infect Immun1997; 65: 2283—2291.
21.
Kleinschmidt S., Wanner GA, Bussmann D. et al. Proinflammatory cytokine gene expression in whole blood from patients undergoing coronary artery bypass surgery and its modulation by pentoxifylline. Shock1998 ; 9: 12—20.
22.
Naldini A., Borrelli E., Cesari S., Giomarelli P., Toscano M.In vitro cytokine production and T-cell proliferation in patients undergoing cardiopulmonary by-pass. Cytokine1995; 7: 165—170.
23.
Hayes MP, Freeman SL, Donnelly RPIFN-gamma priming of monocytes enhances LPS-induced TNF production by augmenting both transcription and mRNA stability. Cytokine1995; 7: 427—435.
24.
Hershman MJ , Appel SH, Wellhausen SR, Sonnenfeld G., Polk Jr HCInterferon-gamma treatment increases HLA-DR expression on monocytes in severely injured patients. Clin Exp Immunol1989; 77: 67—70.
25.
Billiau A.Interferon-gamma: biology and role in pathogenesis. Adv Immunol1996; 62: 61—130.
26.
Baker SP, O'Neill B., Haddon W., Long W.The Injury Severity Score: a method for describing patients with multiple injuries and evaluating emergency care. J Trauma1974; 14: 187—196.
27.
Svoboda, P. , Kantorova I., Ochmann J.Dynamics of interleukins 1, 2, and 6 and tumor necrosis factor alpha in multiple trauma patients. J Trauma1994; 36: 336—340.
28.
Roumen RM, Hendriks T., van der Ven Jongekrijg J. et al. Cytokine patterns in patients after major vascular surgery, hemorrhagic shock, and severe blunt trauma. Relation with subsequent adult respiratory distress syndrome and multiple organ failure. Ann Surg1993; 218: 769—776.
29.
De AK, Kodys K., Puyana JC, Fudem G., Savoie P., Miller Graziano CLElevated IL-8 production by trauma patients' monocytes is associated with elevated secretion of TNF alpha. Shock1995 ; 4: 171—177.
30.
DiPiro JT, Howdieshell TR, Goddard JK, Callaway DB, Hamilton RG, Mansberger Jr ARAssociation of interleukin-4 plasma levels with traumatic injury and clinical course. Arch Surg1995; 130: 1159—1162.
31.
Ertel W., Keel M., Bonaccio M. et al. Release of anti-inflammatory mediators after mechanical trauma correlates with severity of injury and clinical outcome. J Trauma1995; 39: 879—885.
32.
Neidhardt R. , Keel M., Steckholzer U. et al. Relationship of interleukin-10 plasma levels to severity of injury and clinical outcome in injured patients. J Trauma1997; 42: 863—870.
33.
Ayala A., Meldrum DR, Perrin MM, Chaudry IHThe release of transforming growth factor-beta following haemorrhage: its role as a mediator of host immunosuppression. Immunology1993; 79: 479—484.
34.
Faist E., Mewes A., Baker CC et al. Prostaglandin E2 (PGE2)-dependent suppression of interleukin alpha (IL-2) production in patients with major trauma. J Trauma1987; 27: 837—848.
35.
Markewitz A. , Faist E., Lang S., Endres S., Fuchs D., Reichart B.Successful restoration of cell-mediated immune response after cardiopulmonary bypass by immunomodulation. J Thorac Cardiovasc Surg1993; 105: 15—24.
36.
Faist E., Ertel W., Baker CC, Heberer G.Terminal B-cell maturation and immunoglobulin (Ig) synthesis in vitro in patients with major injury. J Trauma1989; 29: 2—9.
37.
Fabian TC, Croce MA, Fabian MJ et al. Reduced tumor necrosis factor production in endotoxin-spiked whole blood after trauma: experimental results and clinical correlation. Surgery1995; 118: 63—72.
38.
Börgermann J., Friedrich I., Flohé S. et al. Tumor necrosis factor-α production in whole blood after cardiopulmonary bypass. Down-regulation caused by circulating cytokine-inhibitory activity. J Thorac Cardiovasc Surg; 2001; In press
39.
Hayes MP, Zoon KCPriming of human monocytes for enhanced lipopolysaccharide responses: expression of alpha interferon, interferon regulatory factors, and tumor necrosis factor . Infect Immun1993; 61: 3222—3227.
40.
Polk Jr HC, Cheadle WG, Livingston DH et al. A randomized prospective clinical trial to determine the efficacy of interferon-gamma in severely injured patients. Am J Surg1992; 163: 191—196.
41.
Dries DJInterferon gamma in trauma-related infections. Intensive Care Med1996; 22 (Suppl 4): S462—S467.
42.
Livingston DH, Loder PA, Kramer SM, Gibson UE, Polk Jr HCInterferon gamma administration increases monocyte HLA-DR antigen expression but not endogenous interferon production. Arch Surg1994; 129: 172—178.
43.
Döcke WD, Randow F., Syrbe U. et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med1997; 3: 678—681.
44.
Ertel W., Keel M., Neidhardt R. et al. Inhibition of the defense system stimulating interleukin-12 interferon-gamma pathway during critical illness. Blood1997; 89: 1612—1620.
Dries DJ, Walenga JM, Hoppensteadt D., Fareed J.Molecular markers of hemostatic activation and inflammation following major injury: effect of therapy with IFN-gamma. J Interferon Cytokine Res1998; 18: 327—335.
